Warfvinges väg 35
About BioArctic ABBioArctic AB is a Swedish privately held research-based biopharmaceutical company founded in 2003. The company’s mission is to provide new and effective treatments for patients with disorders in the central nervous system. Its proprietary technology and dedicated personnel have made it possible to develop new immunotherapeutic approaches to neurodegenerative diseases. We focus on therapy areas with a large medical need such as Alzheimer’s disease, Parkinson’s disease and spinal cord injury.
CEO: Gunilla Osswald
CSO: Christer Möller
CMO: Hans Basun
Please click here for BioArctic job opportunities.
Please click here for clinical trial information.
70 articles with BioArctic AB
BioArctic AB announced that the company has been awarded the 2020 Allbright Award for its focused work with gender equality.
Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET
BioArctic AB to publish the company's Interim Report for the period January - September 2020 on Wednesday, October 14, 2020, at 08:00 a.m. CET.
BioArctic AB announced that the company's partner Eisai presented the latest data from the open-label extension of the Phase 2b study with the investigational BAN2401 in early Alzheimer's disease.
BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020
BioArctic AB announced that the company's partner Eisai will present the study design of the Phase 3 program AHEAD 3-45 at the Alzheimer's Association International Conference 2020 on July 27-31. In the study, the therapeutic effect of drug candidate BAN2401 on the progression of preclinical, asymptomatic, Alzheimer's disease will be investigated.
BioArctic AB announced that its business partner Eisai, in collaboration with Alzheimer's Clinical Trials Consortium and Biogen, has initiated a new global Phase 3 clinical study with BAN2401, an anti-amyloid beta protofibril antibody.
Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET
BioArctic AB to publish the company's Interim Report for the period January - June 2020 on Friday, July 1, 2020, at 08:00 a.m. CET.
BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease
BioArctic AB and University of Oslo, Institute of Clinical Medicine, announced that they have signed a research collaboration agreement to increase the understanding of Apolipoprotein E as a drug target for Alzheimer's disease.
BioArctic AB (publ) ( Nasdaq Stockholm : BIOA B ) announces that seven members of the company's Board and management today have exercised options to purchase shares in the company in accordance with the existing option agreements with the principal owners of BioArctic AB. Seven members of BioArctic's Board of Directors and management,
The general meeting adopted the income statement and balance sheet for the company and for the group in accordance with submitted accounting documents.
BioArctic has not experienced any noteworthy disruptions to its operations owing to the COVID-19 pandemic.
Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET
BioArctic AB to publish the company's Interim Report for the period January - March 2020 on Wednesday, April 22, 2020, at 08:00 a.m. CET..
BioArctic AB announced that the company's partner Eisai will include Swedish clinics in the confirmatory Phase 3 study of the drug candidate BAN2401.
BioArctic AB will be strengthening its management team in 2020 through two strategic recruitments.
BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference
BioArctic AB announced that presentations related to BAN2401 will be given at the 12th Clinical Trials on Alzheimer's Disease conference to be held December 4-7 in San Diego, California, USA.
BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury
BioArctic AB announced the results of an interim analysis of a Phase 1/2 study of SC0806 in patients with complete spinal cord injury.
The Annual General Meeting of BioArctic AB on May 9, 2019, adopted instructions regarding the appointment of the Nomination Committee.
BioArctic and Eisai presented new data regarding BAN2401 at the Alzheimer’s Association International Conference® (AAIC®) in July that confirmed BAN2401’s unique characteristics and was consistent with previously presented results
BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019
BioArctic AB announces that new data related to BAN2401 were presented on July 17.
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University and researcher, received one of the world's most prestigious awards in Alzheimer's disease research.
BioArctic AB announced that presentations related to BAN2401 will be given at the Alzheimer's Association International Conference® 2019 to be held July 14-18 in Los Angeles, USA.